vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $22.0M, roughly 1.7× BGSF, INC.). BGSF, INC. runs the higher net margin — -5.3% vs -161.8%, a 156.5% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -9.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-71.3M).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
BGSF vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $38.3M |
| Net Profit | $-1.2M | $-61.9M |
| Gross Margin | 35.0% | 99.0% |
| Operating Margin | -17.6% | -169.0% |
| Net Margin | -5.3% | -161.8% |
| Revenue YoY | -9.4% | 407.0% |
| Net Profit YoY | -18.2% | -4.7% |
| EPS (diluted) | $-0.12 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $38.3M | ||
| Q3 25 | $26.9M | $32.1M | ||
| Q2 25 | $23.5M | $26.4M | ||
| Q1 25 | $20.9M | $16.5M | ||
| Q4 24 | $24.3M | $7.6M | ||
| Q3 24 | $29.8M | $6.1M | ||
| Q2 24 | $25.7M | — | ||
| Q1 24 | $24.5M | — |
| Q4 25 | $-1.2M | $-61.9M | ||
| Q3 25 | $-5.8M | $-67.3M | ||
| Q2 25 | $-3.7M | $-92.6M | ||
| Q1 25 | $-722.0K | $-129.6M | ||
| Q4 24 | $-981.0K | $-59.2M | ||
| Q3 24 | $-804.0K | $-85.7M | ||
| Q2 24 | $-761.0K | — | ||
| Q1 24 | $-792.0K | — |
| Q4 25 | 35.0% | 99.0% | ||
| Q3 25 | 35.9% | 99.4% | ||
| Q2 25 | 35.8% | 99.5% | ||
| Q1 25 | 36.2% | 99.6% | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | -169.0% | ||
| Q3 25 | -3.5% | -173.5% | ||
| Q2 25 | -18.8% | -269.8% | ||
| Q1 25 | 1.6% | -390.1% | ||
| Q4 24 | -15.7% | -919.0% | ||
| Q3 24 | -3.4% | -1314.3% | ||
| Q2 24 | -5.7% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | -5.3% | -161.8% | ||
| Q3 25 | -21.6% | -209.8% | ||
| Q2 25 | -15.9% | -350.3% | ||
| Q1 25 | -3.5% | -784.9% | ||
| Q4 24 | -4.0% | -783.4% | ||
| Q3 24 | -2.7% | -1404.0% | ||
| Q2 24 | -3.0% | — | ||
| Q1 24 | -3.2% | — |
| Q4 25 | $-0.12 | $-0.06 | ||
| Q3 25 | $-0.52 | $-0.07 | ||
| Q2 25 | $-0.34 | $-0.10 | ||
| Q1 25 | $-0.06 | $-0.15 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | $-0.07 | $-0.14 | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $-500.5M |
| Total Assets | $57.8M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | $41.2M | $257.8M | ||
| Q2 25 | $2.8M | $153.7M | ||
| Q1 25 | $2.0M | $61.6M | ||
| Q4 24 | $32.0K | $149.8M | ||
| Q3 24 | $262 | $130.4M | ||
| Q2 24 | $226 | — | ||
| Q1 24 | $50 | — |
| Q4 25 | $48.1M | $-500.5M | ||
| Q3 25 | $50.7M | $-524.3M | ||
| Q2 25 | $78.3M | $-570.7M | ||
| Q1 25 | $81.8M | $-591.4M | ||
| Q4 24 | $82.3M | $-489.1M | ||
| Q3 24 | $82.9M | $-745.1M | ||
| Q2 24 | $83.2M | — | ||
| Q1 24 | $83.6M | — |
| Q4 25 | $57.8M | $501.9M | ||
| Q3 25 | $83.6M | $519.0M | ||
| Q2 25 | $149.7M | $402.1M | ||
| Q1 25 | $152.3M | $303.8M | ||
| Q4 24 | $150.1M | $382.9M | ||
| Q3 24 | $157.3K | $364.6M | ||
| Q2 24 | $159.8K | — | ||
| Q1 24 | $170.6K | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-70.4M |
| Free Cash FlowOCF − Capex | $1.7M | $-71.3M |
| FCF MarginFCF / Revenue | 7.6% | -186.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-70.4M | ||
| Q3 25 | $-4.8M | $-68.9M | ||
| Q2 25 | $2.2M | $-79.7M | ||
| Q1 25 | $1.1M | $-85.9M | ||
| Q4 24 | $3.2M | $-85.1M | ||
| Q3 24 | $6.5M | $-98.8M | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $7.4M | — |
| Q4 25 | $1.7M | $-71.3M | ||
| Q3 25 | $-4.9M | $-69.6M | ||
| Q2 25 | $2.1M | $-80.8M | ||
| Q1 25 | $1.0M | $-87.0M | ||
| Q4 24 | $2.5M | $-87.3M | ||
| Q3 24 | $6.5M | $-101.6M | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $6.9M | — |
| Q4 25 | 7.6% | -186.2% | ||
| Q3 25 | -18.1% | -217.2% | ||
| Q2 25 | 9.1% | -305.9% | ||
| Q1 25 | 5.0% | -526.9% | ||
| Q4 24 | 10.2% | -1155.4% | ||
| Q3 24 | 21.7% | -1663.2% | ||
| Q2 24 | 28.5% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.4% | 2.3% | ||
| Q2 25 | 0.0% | 4.1% | ||
| Q1 25 | 0.1% | 6.8% | ||
| Q4 24 | 3.0% | 28.0% | ||
| Q3 24 | 0.0% | 45.7% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 2.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
IBRX
Segment breakdown not available.
